Antibody Drug Conjugates: windows of opportunity
Drug Target Review
JULY 4, 2023
However, ADCs are a nascent therapeutic option and real-world clinical data is emerging daily that is shedding light on the utility and potential of this exciting modality to deliver against its promise. Petra holds a D.Phil in synthetic organic chemistry and am MBA from Imperial College London. 2021 Jul 8;110(5):1216–30.
145 
Let's personalize your content